Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today
announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling
Services, providing an unparalleled, personalized solution for surgeons and
patients across partial and total knee arthroplasty procedures. It is
exclusively for use with the CORI Surgical System - the only orthopaedic
robotic-assisted system to offer either intraoperative image-free or image-based
registration, enabling the surgeon to choose whether or not to perform a pre-
operative MRI scan.
Delivering solutions for differing patient types coupled with planning and
execution tools is essential to personalizing surgery. Robotic-assisted surgery
can improve accuracy and reproducibility, and may lead to better patient
outcomes compared to conventional techniques.(1-3)
The first procedures using CORIOGRAPH Pre-Operative Planning and Modeling
Services and RI.KNEE ROBOTICS 3.0 Software were recently completed by Dr. Steven
Haas, Orthopaedic Surgeon and Chief of Knee Service at the Hospital for Special
Surgery in New York. He stated, "We are now truly personalizing surgery and
advancing efficiencies with RI.KNEE 3.0 and CORIOGRAPH services. Providing the
ability to choose the right imaging modality represents the next paradigm for
individualized patient care and brings orthopaedic robotics to another level."
The CORI Surgical System offers proprietary tools and AI-driven software across
the full suite of procedure solutions to deliver a robotics platform that is
flexible and scalable across joint arthroplasty indications. Built on 15+ years
of clinical expertise and over 350,000 image-based surgery plans, CORIOGRAPH
Pre-Operative Planning and Modeling Services is where the surgical journey
begins. It is designed to optimize procedures and enable intraoperative
efficiencies in conjunction with new RI.KNEE ROBOTICS 3.0 Software, which
includes:

  * Image-agnostic registration functionality, including image-based and image-
    free offerings
  * Optimized knee offering with support for pre-cut tensioning with the CORI
    Digital Tensioner for partial, total and revision knees

"The introduction of CORIOGRAPH Pre-Operative Planning and Modeling Services
signals the next big step in personalized surgery and the evolution of our
robotics ecosystem. This combined with the CORI Digital Tensioner will further
advance efficiencies for robotic-assisted procedures," said Mayank Shandil, SVP,
Global Marketing - Reconstruction and Robotics at Smith+Nephew.
To learn more about the CORI Surgical System and Smith+Nephew's digital surgery
applications across a range of joint arthroplasty indications, please visit
https://www.smith-nephew.com/en/health-care-
professionals/products/orthopaedics/cori
- ends -
Enquiries
Media

Dave Snyder          +1 (978) 749-1440
Smith+Nephew      david.snyder@smith-nephew.com (mailto:david.snyder@smith-

nephew.com)
References
1. Matsumoto T, Nakano N, Hayashi S, et al. Prosthetic orientation, limb

    alignment, and soft tissue balance with bi-cruciate stabilized total knee
    arthroplasty: a comparison between the handheld robot and conventional
    techniques. International Orthopaedics 2023;47(6):1473-80. doi:
    10.1007/s00264-023-05737-6

2. Crizer MP, Haffar A, Battenberg A, et al. Robotic Assistance in

    Unicompartmental Knee Arthroplasty Results in Superior Early Functional
    Recovery and Is More Likely to Meet Patient Expectations. Advances in
    Orthopedics 2021;2021 doi: 10.1155/2021/4770960

3. Negrín R, Duboy J, Iñiguez M, et al. Robotic-assisted vs conventional

    surgery in medial unicompartmental knee arthroplasty: a clinical and
    radiological study. Knee Surg Relat Res 2021;33(1):5. doi:
    10.1186/s43019-021-00087-2 (published Online First: 2021/02/14)

About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair,
regeneration and replacement of soft and hard tissue. We exist to restore
people's bodies and their self-belief by using technology to take the limits off
living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this
mission every day, making a difference to patients' lives through the excellence
of our product portfolio, and the invention and application of new technologies
across our three global business units of Orthopaedics, Sports Medicine & ENT
and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and
generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of
the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to
refer to Smith & Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com
(http://www.smith-nephew.com/)and follow us on X
(http://www.twitter.com/smithnephewplc), LinkedIn
(http://www.linkedin.com/company/smith-%26-nephew), Instagram
(https://www.instagram.com/smithnephewmeded/) or Facebook
(http://www.facebook.com/smithnephewplc).
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and trading
profit margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-
placed", "believe", "estimate", "expect", "target", "consider" and similar
expressions are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and
other important factors that could cause actual results to differ materially
from what is expressed or implied by the statements. For Smith+Nephew, these
factors include: conflicts in Europe and the Middle East, economic and financial
conditions in the markets we serve, especially those affecting healthcare
providers, payers and customers; price levels for established and innovative
medical devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product defects or recalls
or other problems with quality management systems or failure to comply with
related regulations; litigation relating to patent or other claims; legal and
financial compliance risks and related investigative, remedial or enforcement
actions; disruption to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including acquisitions
and disposals, our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions or other
changes we make in our business plans or organisation to adapt to market
developments; relationships with healthcare professionals; reliance on
information technology and cybersecurity; disruptions due to natural disasters,
weather and climate change related events; changes in customer and other
stakeholder sustainability expectations; changes in taxation regulations;
effects of foreign exchange volatility; and numerous other matters that affect
us or our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange Commission under
the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's
most recent annual report on Form 20-F, which is available on the SEC's website
at www. sec.gov, for a discussion of certain of these factors. Any forward-
looking statement is based on information available to Smith+Nephew as of the
date of the statement. All written or oral forward-looking statements
attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does
not undertake any obligation to update or revise any forward-looking statement
to reflect any change in circumstances or in Smith+Nephew's expectations.
(? )Trademark of Smith+Nephew. Certain marks registered in US Patent and
Trademark Office.
Â